CLINDAPASSNCT07267013
Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 29 words Show 5 more changesShow less
- Primary completion date changed from estimate of Jul 21, 2026 to Nov 3, 2026
- Study completion pushed from Oct 21, 2026 to Feb 3, 2027
- Secondary endpoints: details revised at 2 of 7 entries
- Study description revised
- Site details revised
Notable Recruitment openedv3 Show 4 more changesShow less
- Primary completion date: Jul 30, 2026 to Jul 21, 2026
- Study completion date: Oct 30, 2026 to Oct 21, 2026
- Start date changed from estimate of Mar 30, 2026 to Apr 21, 2026
- Site details revised
- Notable Start date: Jan 15, 2026 to Mar 30, 2026
- Primary completion date: Jul 15, 2026 to Jul 30, 2026
- Study completion date: Jul 15, 2026 to Oct 30, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Plasma clindamycin concentrations
Timeframe: H0 (at incision), then every hour, and at the end of surgery (defined as sternal closure)
Secondary (7)
Determine the pharmacokinetic parameters of clindamycin under ECC
Determine the factors of variability in clindamycin pharmacokinetics for patients under ECC surgery
Determining the diffusion of clindamycin in pericardial fatty tissue
Description of adverse events according to NCI CTCAE V5 criteria
Adherence to Good Clinical Practice clindamycin injection protocol
Show 2 moreShow less
Rate of post-operative mediastinitis (up to 3 months post-operatively)
Post-op morbidity and mortality
Arms and interventions
ClindamycinExperimental
Drugs: Clindamycin
Sites
1 site in 1 country
- CHU NantesNantes, France